Exact Sciences stock is trading -25.2% below its average target price of $92.82 after marking a 7.5% during today's evening session. Analysts are giving the mid-cap Medical Specialities company an average rating of buy and target prices ranging from $66.0 to $120.0 per share.
Exact Sciences's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.1%. The stock's short ratio is 4.68. The company's insiders own 0.94% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 90.7%. In conclusion, we believe there is mixed market sentiment regarding Exact Sciences.
Institutions Invested in Exact Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | JP Morgan Chase & Company | 10% | 18,292,619 | $1,270,056,542 |
| 2023-09-30 | Vanguard Group Inc | 10% | 17,444,693 | $1,211,185,040 |
| 2023-09-30 | Blackrock Inc. | 6% | 11,575,558 | $803,690,995 |
| 2023-09-30 | Wellington Management Group, LLP | 6% | 10,820,873 | $751,293,215 |
| 2023-09-30 | Capital World Investors | 4% | 6,928,647 | $481,055,963 |
| 2023-09-30 | ARK Investment Management, LLC | 3% | 6,280,931 | $436,085,041 |
| 2023-09-30 | State Street Corporation | 2% | 4,510,603 | $313,171,167 |
| 2023-09-30 | Baillie Gifford and Company | 2% | 4,066,330 | $282,325,293 |
| 2023-09-30 | Artisan Partners Limited Partnership | 2% | 3,961,514 | $275,047,918 |
| 2023-09-30 | Ameriprise Financial, Inc. | 2% | 3,239,648 | $224,928,761 |
